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Immunoglobulin (Ig) gene rearrangements and oncogenic translocations are routinely
assessed during the characterization of B cell neoplasms and stratification of patients with
distinct clinical and biological features, with the assessment done using Sanger sequencing,
targeted next-generation sequencing, or fluorescence in situ hybridization (FISH). Currently,
a complete Ig characterization cannot be extracted from whole-genome sequencing (WGS)
data due to the inherent complexity of the Ig loci. Here, we introduce IgCaller, an algorithm
designed to fully characterize Ig gene rearrangements and oncogenic translocations from
short-read WGS data. Using a cohort of 404 patients comprising different subtypes of B cell
neoplasms, we demonstrate that IgCaller identifies both heavy and light chain rearrange-
ments to provide additional information on their functionality, somatic mutational status,
class switch recombination, and oncogenic Ig translocations. Our data thus support IgCaller
to be a reliable alternative to Sanger sequencing and FISH for studying the genetic properties
of the Ig loci.
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Mature normal and tumor B cells express a uniqueimmunoglobulin (Ig) gene rearrangement. This indivi-dual Ig gene is formed during the first steps of B cell
development in the bone marrow where both heavy (IGH) and
light chains [kappa (IGK) or lambda (IGL)] are rearranged by a
hierarchical process in which distant variable (V), diversity (D,
only in the IGH locus), and joining (J) genes are joint through
deletions of the genomic sequence between them1. During this
process of cut-and-joining of the different genes, random
nucleotides known as N nucleotides are added in the junctions to
increase the diversity of the Ig repertoire. Later on, upon antigen
activation, the Ig gene rearrangements undergo further diversi-
fication by the process of somatic hypermutation (SHM), which
introduces mutations in the V(D)J regions, and class switching of
the heavy chain in the germinal center of the lymphoid follicles1.
The identification of a clonal B cell population (i.e. large B cell
population expressing the same Ig) in the context of a lymphoid
proliferation is used as a marker of leukemia/lymphoma diag-
nosis. Besides, the presence of SHM in the V(D)J region of the
IGH is a surrogate imprint of the cell of origin of the lymphoid
neoplasm with marked clinical implications. In chronic lym-
phocytic leukemia (CLL)2,3 and mantle cell lymphoma (MCL)4,
the identification of SHM distinguishes subtypes of tumors
[mutated (M-IGHV) or unmutated (U-IGHV)] with different
clinical and biological behavior. In CLL, different prognostic
models incorporate the IGHV mutational status5, and guidelines
recommend its analysis either at diagnosis or before treatment
initiation6. In addition, tumors carrying highly similar Ig (i.e.
stereotyped Ig)7, specific Ig light chain (IGLC) rearrangements8,
or class switch recombination (CSR) of the constant region of the
heavy chain9 characterize subsets of patients with distinct clinical
and biological features. Besides, the detection of oncogenic Ig
translocations genome-wide helps the diagnosis of different
neoplasms such as MCL, follicular lymphoma and Burkitt lym-
phoma, while stratifies patients with distinct clinical outcomes in
multiple myeloma (MM) and diffuse large B cell lymphoma
(DLBCL)10.
The analysis of the rearranged Ig gene is currently performed
both in the clinical routine and research by Sanger sequencing
(SSeq)6 or by specific targeted next-generation sequencing (NGS)
protocols11. Of note, independent assays are required to assess the
IGH, IGK and IGL sequences12. Once the rearranged sequence is
obtained, several tools are available to identify the V(D)J genes, its
functionality (i.e. productive or unproductive) and mutational
status (IMGT/V-QUEST13,14 or IgBLAST15), and stereotype
(ARResT/AssignSubsets16). On the other hand, Ig translocations
are routinely assessed by fluorescence in situ hybridization (FISH)
and/or conventional cytogenetics in the clinical setting. Although
short-read whole-genome sequencing (WGS) of B cell neoplasms
should store the information to reconstruct the entire Ig gene, the
high genomic complexity of the Ig loci has prevented its analysis
using the current bioinformatic pipelines. The decreasing cost of
short-read WGS linked with its ability to characterize the entire
genomic landscape of these neoplasms in a single experiment17,
even if complex and heterogeneous18, suggests that WGS could
enter into the clinical setting in the near future.
Here we present IgCaller, a fast, easy-to-run, python program
designed to reconstruct the entire Ig gene rearrangements from
short-read WGS data of lymphoid neoplasms. We demonstrat the
accuracy of IgCaller using WGS data of 404 B cell neoplasms with
available SSeq/NGS of the IGH V(D)J and/or IGLC and isotype
expression for comparison: 230 cases of CLL in two independent
cohorts of 152 (cohort 1 [C1])18,19 and 78 (cohort 2 [C2]), 64
cases of MCL20, 30 MM21, 73 DLBCL22, and 7 mature B cell non-
Hodgkin lymphomas (B-NHL) (Supplementary Data 1).
Results
Overview of IgCaller. IgCaller takes as input the WGS aligned
reads (BAM file)23–25 to assemble the rearranged IGH V(D)J
genes, IGK and IGL VJ genes, and to identify the presence of CSR
and genome-wide Ig translocations. IgCaller also determines the
identity of the rearranged sequences compared to the germ line of
the patients or reference genome. Although IgCaller also pro-
duces a preliminary analysis of the functionality of the rearranged
sequences, these sequences can be used as input of downstream
programs such as IMGT/V-QUEST or IgBLAST, as usually done
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Fig. 1 Overview of IgCaller and Ig loci at short-read WGS level. a Bioinformatic steps to fully characterize the rearranged Ig gene from short-read WGS
data. IgCaller extracts the rearranged sequences from already aligned reads (BAM file). The output of IgCaller might be used as input to downstream
specific programs for a complete Ig annotation. b Schema of the Ig loci at B cell genome level (top) and reference genome level (bottom) for the different
loci/rearrangements analyzed by IgCaller. Of note, although the IGK locus is oriented on the negative strand, the IGKV4-1, IGKV5-2, and IGKV genes
within the distal cluster are inverted and therefore oriented on the positive strand. Thus, rearrangements involving these IGKV genes are formed through
inversions rather than deletions. The WGS reads that cover the rearrangements and are used by IgCaller are depicted in each scenario. White arrows
represent the coding strand.
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IgCaller relies on two sets of reads to identify the break points
at base pair resolution and to reconstruct the rearranged V(D)J
sequences (Fig. 1b): (i) split reads (a fraction of the read maps to
one location while the other fraction of the same read maps to a
different location of the genome) spanning the boundaries of both
V and J genes [note that in the IGH loci, reads do no map to the
D gene due to its small length]; and (ii) abnormal insert size reads
(reads with anomalous distance between read pairs) in which one
read of a pair maps to a V gene and the other to a J gene. Once
the rearranged V–J gene is found by combining both sets of reads,
the consensus unmapped sequence of the split reads is used to
extract the sequence containing the N nucleotides-D gene-N
nucleotides (IGH locus) or the N nucleotides (IGK/IGL loci). The
germ line sequence of the patient is used, if available, to consider
potential polymorphisms when assessing the identity of the
rearranged sequence to the germ line. The read depth before and
after the potential CSR identified is compared to determine the
presence of isotype switching26. Besides, using both types of reads
as well as paired reads aligning to different chromosomes,
IgCaller identifies genome-wide rearrangements (deletions, inver-
sions, gains and translocations) involving any of the Ig loci. A
detailed explanation of the methodological framework and
instructions to run IgCaller might be found in the “Methods”.
Ig heavy chain rearrangements and identity. Using the WGS of
404 B cell neoplasms, IgCaller identified a complete productive
IGH gene rearrangement [V(D)J] in 131 (86%) C1-CLL, 75 (96%)
C2-CLL, 63 (98%) MCL, 21 (70%) MM, 44 (60%) DLBCL, and in
all 8 B-NHL. A partial (VJ) rearrangement was detected in 10
(7%) C1-CLL and 1 (3%) MM (Fig. 2a, Supplementary Data 2–7).
Two distinct productive IGHV-IGHD-IGHJ gene rearrangements
were observed in 2 cases (1 CLL, 1 MCL). These results were fully
concordant with the SSeq/NGS of 139 C1-CLL, 67 C2-CLL, 60
MCL, and 1 B-NHL (Supplementary Data 2–7). Small dis-
crepancies (only J or V disagreement) were found when the J (n
= 7) or V (n= 1) genes identified by SSeq based on identity
(IMGT/V-QUEST) did not correspond to the rearranged genes
detected by IgCaller, but were the second scoring genes in IMGT/
V-QUEST, suggesting that our non-identity WGS-based
approach might be more accurate in these scenarios (Supple-
mentary Fig. 1). Contrarily, rearrangements within genes not
annotated in the reference genome used by IgCaller could lead to
incongruent results. These errors occurred in five CLL patients
carrying rearrangements involving IGHV5-10-1 (n= 4) or
IGHV7-4-1 (n= 1), which are not annotated in the hg19 genome
build used. All these rearrangements were recovered after aligning
the WGS data to the hg38 reference genome (Supplementary
Fig. 2). Of note, the sequence of the complete IGH gene rear-
rangement identified by IgCaller could be used to determine the
stereotypy of the CLL cases (Supplementary Data 2 and 3).
IgCaller also reports the unproductive rearrangements. In this
regard, IGH unproductive rearrangements were identified in 51
cases, all but four carrying productive rearrangements in the
other allele (Supplementary Data 8). We verified by NGS 7 ran-
domly selected IGH unproductive rearrangements (Supplemen-
tary Data 8).
Next, the comparison of the percentage of identity of the
rearranged sequence to the germ line in 139 C1-CLL, 67 C2-CLL,
and 60 MCL obtained by SSeq/NGS and IgCaller showed a high
significant correlation and concordance in all three cohorts
(Fig. 2b, Supplementary Fig. 3). Only 2 (0.8%) cases with a
complete rearrangement and a partial rearrangement by WGS,
R = 0.91; p=2.19e–54
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N cases: 2 11 8 2 129
Fig. 2 Benchmarking of IgCaller: characterization of the IGH locus. a Bar plot showing the percentage of cases with productive IGH rearrangements by
IgCaller in each cohort. b Dot plots of the percentage of identity of the rearranged IGHV sequence to the germ line by IgCaller (y axis) and SSeq/NGS (x
axis). The 95% confidence interval is depicted by the light blue area. The gray area highlights cases in which the presence of a high density of clustered
mutations impairs an accurate identification of the percentage of identity. P values are from t-test. c Comparison of the number of mutations associated
with signature 9 (SBS9, left y axis) and the identity of the rearranged sequence both by SSeq and IgCaller (right y axis) in the C1-CLL cohort. Source data
are provided as a Source data file.
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respectively, were differentially classified as M-IGHV or U-IGHV
between SSeq and WGS using the standard cut off of 98%. In line
with this, we observed that WGS reads carrying a high density of
clustered mutations might not align, and therefore the identity of
the rearranged sequence could be overestimated (Supplementary
Fig. 4). However, this non-alignment of highly mutated WGS
reads only affected a minority of CLL cases, and rarely miss-
classified patients as M-IGHV or U-IGHV (Fig. 2b). Besides, the
use of WGS allows the recognition of the germinal center reaction
imprint by the detection of a genome-wide mutational signature
associated to the activity of AID (non-canonical AID or signature
9 [SBS9])18,21,27. The number of mutations associated to
SBS9 significantly correlated with the IGHV gene identity
observed both by SSeq and IgCaller (Supplementary Fig. 5).
Therefore, SBS9 could help to corroborate the mutational status
observed by IgCaller. However, the use of SBS9 alone would have
miss-classified the Ig mutational status of 8 (5%) C1-CLL
patients, highlighting that a proper analysis of the Ig gene
rearrangement might be needed to correctly stratify patients
based on the clinically-accepted cut off of 98% of identity
(Fig. 2c).
Ig light chain rearrangements. A productive IGK or IGL gene
rearrangement was found in 147 (97%) C1-CLL, 76 (97%) C2-
CLL, 64 (100%) MCL, 27 (90%) MM, 45 (62%) DLBCL, and 7
(100%) B-NHL (Supplementary Data 9–14). These results were
fully concordant with the IGLC expression observed by flow
cytometry (FC) (Fig. 3a). Besides, we verified 5 randomly selected
inversion-IGK productive rearrangements by SSeq (Fig. 1b,
Supplementary Fig. 6, Supplementary Data 15). Furthermore,
IgCaller is also able to characterize the deletions occurring within
the kappa deleting element (Kde) and the intron recombination
signal sequence (RSS) allowing for a full characterization of the
IGK locus28. In this regard, IgCaller identified 178 Kde-RSS
deletions, 139 Kde-IGKV deletions, and 5 RSS-IGKV deletions
(Supplementary Data 16). We confirmed the presence of these
deletions by PCR in three selected cases (Supplementary Fig. 7).
IgCaller also identified 246 unproductive/unexpressed IGK/L
rearrangements in 177 cases (Supplementary Data 16). Con-
sidering that virtually all these cases expressed a productive IGK/
L rearrangement, this finding emphasizes the sensitivity of
IgCaller to detect multiple rearrangements.
The ability to determine the IGLC rearrangements from WGS
data is of clinical relevance due to its prognostic value. In fact, we
identified IGLV3-21 in 25/223 (11%) CLL, which was associated
with a shorter time to first treatment (TTFT) in M-IGHV cases,
and with a shorter overall survival independently of the IGHV
mutational status, as recently suggested (Fig. 3b)8.
Class switch recombination. IgCaller identified the CSR
matching the isotype expressed by FC analysis in 27/30 (90%)
MM (Fig. 3c, Supplementary Data 17). Two of the three poten-
tially discordant cases with IgG or IgM by WGS expressed only
IGLC by FC. In the latter case, two IGH translocations also
detected by IgCaller caused the loss of the constant IGH region of
both alleles leading to sole IGLC expression (Supplementary
Fig. 8). Overall, IgCaller could not identify the isotype switch in 1
(3%) MM expressing IgG (Supplementary Fig. 8). Next, CSR was
observed in 37/230 (16%) CLL, 2 (3%) MCL, 28 (38%) DLBCL














































































CLL (C1-CLL + C2−CLL)
IGLC expression by FC
p >
 0.1 p <
 0.01
p = 1.81e-13
Time (years from diagnosis)
80
DLBCL





















Overall survival (n=214; number of events=67)





























































 0.017 p =
 0.058












































































































































Fig. 3 Benchmarking of IgCaller: IGLC rearrangements, CSR, and oncogenic Ig translocations. a Agreement between the IGLC productive rearrangement
detected by IgCaller and FC analysis. b TTFT and OS of patients with CLL according to the presence of IGLV3-21 rearrangements. P values for TTFT curves
are from Gray test. P values for the multivariate analysis of OS are from Cox regression. c Comparison of the CSR identified by IgCaller and FC. d TTFT of
CLL patients according to the presence of CSR. P values are from Gray test. e Circular representation of the oncogenic Ig rearrangements (translocations
and deletions) identified by IgCaller genome-wide. Frequencies of recurrent alterations are shown. Source data are provided as a Source data file.
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B cell subtype; and 3, 33%, unclassified], and 4 (57%) B-NHL
(Fig. 3c, Supplementary Data 17–22). The distribution of CSR in
the different tumor types is similar to that observed using FC or
SSeq9,29–31. We confirmed the WGS-derived CSR in 6 randomly
selected CLL cases by FC (Supplementary Fig. 9, Supplementary
Data 18). Noteworthy, the presence of CSR in 18/115 (16%) M-
IGHV identified CLL patients with a tendency to a shorter TTFT
than non-switched M-IGHV CLL (p= 0.058, Fig. 3d). It is known
that CLL with stereotypes #4 and #16, although expressing IgG,
follow an indolent clinical course9,32,33. The stereotypy analysis of
our CLL cases showed that none of them carried these specific
subsets (Supplementary Data 2 and 3).
Oncogenic Ig translocations. IgCaller identified Ig translocations
in 11 (7%) C1-CLL, 5 (6%) C2-CLL, 63 (98%) MCL, 15 (50%)
MM, 34 (47%) DLBCL, and 2 (29%) B-NHL (Supplementary
Data 23). FISH/PCR data available for 54 cases confirmed all the
rearrangements identified by IgCaller in these tumors (Supple-
mentary Data 23). As previously described, the most common Ig
translocation in CLL was the t(14;18) [IGH-BCL2] in seven cases;
the t(11;14) [CCND1-IGH, n= 62] or t(2;11) [IGK-CCND1, n=
1] in all but one MCL (note that this later case had the char-
acteristics of a CyclinD1-negative MCL);34 the t(11;14) [CCND1-
IGH, n= 7], MYC-IG (n= 4), and t(4;14) [NSD2-IGH, n= 2] in
MM; and the t(14;18) [IGH-BCL2, n= 22] and t(3;14) [BCL6-
IGH, n= 5] in DLBCL (Fig. 3e). Of note, IgCaller identified three
Ig rearrangements in two CLL cases [t(6;22) [IRF4-IGL] and t
(1;22) [RCC1-IGL]; IGK insertion in LINC01475] that were not
detected in previous WGS analyses (Supplementary Figs. 10 and
11)18. Similarly, three Ig translocations identified by IgCaller in
DLBCL, two of them involving BCL6, were not previously
reported (Supplementary Data 23)22. Altogether, these results
emphasizes the sensitivity of IgCaller to detect oncogenic Ig
translocation. Besides, the identification of chromosomal altera-
tions within the Ig loci of these samples suggests that the ability of
IgCaller to reconstruct the V(D)J rearrangement is not influenced
by secondary Ig structural events.
Effect of sequencing depth and tumor purity. Two main factors
that might influence the performance of IgCaller are the
sequencing depth (or coverage) and the tumor cell content (or
purity) of the sample. We did not observe a remarkable effect of
the mean coverage of the Ig loci and the percentage of Ig pro-
ductive rearrangements identified in the CLL and MCL cohorts
(mean depth ranging from 11× to 96×) (Fig. 4a, Supplementary
Data 2–4). To further analyze the effect of coverage, we next focus
on 29 cases (21 C1-CLL and 8 MCL) with a mean depth >30×,
tumor purity >90%, and carrying an identified IGH and IGK/L
productive rearrangements by IgCaller. We randomly down-
sampled the initial BAM files to mean coverages ranging from 5×
to 30× (Methods). The sensitivity of IgCaller to detect the com-
plete productive rearrangements was >0.9 at 20× and >0.85 at
15× (Fig. 4b, Supplementary Data 24). Sensitivity started to drop
at 10× (0.72 for IGH and 0.79 for IGK/L), while <15% and
<50% of the IGH and IGK/L rearrangements could be identified
at 5×, respectively. Besides, two cases included in this analysis
carried a CSR expressing IGHG1 that could be identified at 15×.
Similarly, eight cases carried oncogenic translocations that were
called at a minimum coverage of 10× (1), 15× (2), 20× (4), and
25× (1). Also of interest, the IGHV gene identity reported by
IgCaller was minimally effected by sequencing depth (Fig. 4c).
Altogether, these results suggest that IgCaller is robust at
sequencing depths ranging from >15× to 100×, while some
rearrangements can still be identified at lower coverage. We are
not aware of any potential limitation regarding the use of IgCaller
with WGS data with >100× of depth.
To analyze the effect of the tumor cell content, we created in
silico tumor samples at distinct tumor purities (ranging from 5%
to 95%) by mixing at different ratios the previous 29 tumor
samples with their respective non-tumoral WGS reads (Methods).
At a final mean depth of 30×, the sensitivity of IgCaller to detect a
complete IGH rearrangement was >0.85 with tumor purities
>50%, while it was >0.8 with purity >20% for IGK/L (Fig. 4d,
Supplementary Data 25). The limitation to detect a complete IGH
rearrangement at tumor cell contents around 20–35% could be
overcome at 60× of sequencing depth (Fig. 4e, Supplementary
Data 26). Of note, the identity of the IGHV gene was minimally
affected at tumor cell contents >35% when considering 30× WGS
data (Fig. 4f). As expected, the accuracy of the IGHV gene
identity was higher at 60× WGS, particularly for those samples
with low tumor burden (Supplementary Data 26). The sensitivity
of IgCaller was similarly influenced by an increasing contamina-
tion of a polyclonal-like population prepared by mixing 294
tumor samples (Fig. 4g, “Methods”, Supplementary Fig. 12,
Supplementary Data 27). As expected, in the context of
polyclonal contamination IgCaller also identified Ig rearrange-
ments present in the polyclonal population. Next, to demonstrate
that IgCaller might be used to characterize oligoclonal samples, as
suggested by the identification of multiple productive and/or
unproductive IGH and IGK/L rearrangements, we mixed at
different ratios two tumor samples carrying both a productive
and an unproductive rearrangement caused by the presence of
stop codon mutations (“Methods”). IgCaller was able to identify
all four IGH rearrangements with scores calculated based on their
number of reads that fitted with the pre-defined abundance of
each tumor in each mixed sample (Fig. 4h, Supplementary
Data 28). Overall, these data suggest that IgCaller is relatively
stable when normal or polyclonal contamination is present within
a clonal tumor sample. We have also shown that IgCaller is able
to characterize oligoclonal scenarios carrying both productive and
unproductive gene rearrangements.
Comparison of IgCaller to other available algorithms. Finally,
we aimed to compare the performance of IgCaller to other
available algorithms. After an exhaustive search we did not find
any study that demonstrated that Ig gene rearrangements could
be extracted from short-read WGS data. The lack of algorithms to
reconstruct the Ig gene from short-read WGS data contrasts with
the available set of programs to perform this analysis from
repertoire sequencing (Rep-Seq) data, which specifically amplify
the entire Ig sequence using long reads and specific primers35 as
well as RNA-seq data36–38. Nonetheless, one of the programs
(MiXCR)36 uses a general framework that allows the analysis of
the B cell receptor from both RNA and DNA sequencing data by
starting from raw sequences (FASTQ files). In order to compare
the performance of both programs, we run MiXCR on 194 tumor
samples (136 C1-CLL and 58 MCL). MiXCR identified the same
IGH CDR3 sequence compared to SSeq/IgCaller in all cases
analyzed, with only subtle differences in seven cases (Supple-
mentary Data 29). Similarly, the same V, D, and J genes were
identified in 174/194 (90%) cases. The remaining cases differed in
the D or V gene (8%, 4%) or had multiple potential V or J genes
reported according to MiXCR (12%, 6%). These discrepancies in
the identification of the V, D and J genes are in line with the fact
that MiXCR did not report the complete V(D)J sequence in any
of the samples analyzed. The lack of the full V(D)J sequence
impaired the characterization of the IGHV identity using MiXCR
in the studied low-coverage, short-read WGS data (Supplemen-
tary Data 29).
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Discussion
The characterization of Ig gene rearrangements and oncogenic
translocations is an important diagnostic and prognostic para-
meter in different B cell neoplasms, and guide the management of
the patients2–4,6,10. In spite of the expansion of WGS analyses in
research and clinical settings, these rearrangements are still stu-
died using SSeq, NGS, and/or FISH due to the inherent com-
plexity of the Ig loci. In this report, we describe that the
rearranged Ig genes of B cell neoplasms, including CSR and
oncogenic Ig translocations, can be fully reconstructed from
short-read WGS data. To this aim, we developed IgCaller, an
algorithm that uses standard aligned BAM files to characterize the
Ig gene rearrangements without the need of any additional pre-
processing step. The usage of already aligned WGS data might
facilitate the implementation of IgCaller in virtually any bioin-
formatic pipeline, and will contribute to elucidate the genomic
landscape of B cell lymphomas and leukemias using a single
approach17.
IgCaller reconstructed the complete Ig gene (IGH and IGK/L
productive rearrangements) of 79% of 404 B cell neoplams with
>98% accuracy when compared with standard SSeq/NGS and FC
analyses. The characterization of the complete Ig gene was higher
in CLL (87%) and MCL (98%) than in MM (63%) and DLBCL
(41%), probably due to the higher number of somatic mutations.
At least one IGH or IGK/L productive rearrangement was seen in
99% CLL, 100% MCL, 97% MM, and 81% DLBCL. The sensitivity
of IgCaller is similar to that observed with SSeq39. Besides, we
observed a highly significant correlation and concordance
between the identity of the rearranged IGHV gene sequences
obtained by IgCaller and SSeq/NGS. IgCaller also determined the
presence of IGLC rearrangements, CSR and oncogenic Ig trans-
locations of clinical value in these neoplasms. Of note, some Ig
translocations detected by IgCaller were not recognized in pre-
vious analyses, emphasizing the sensitivity of our algorithm18,22.
We have shown that IgCaller is stable at low sequencing depths
(i.e. 10×), although its sensitivity increases with coverage. Simi-
larly, normal in tumor contamination had a minimal effect on the
sensitivity and specificity of IgCaller, especially when analyzing
60× WGS data. It is important to highlight that IgCaller is not
designed to work with polyclonal samples (i.e. normal B cell
populations); an analysis that indeed is impaired by the low
coverage of WGS. To this aim, other available methodologies
(Rep-Seq or RNA-seq)35 and tools (such as MiXCR)36 might be
more appropriate. These approaches might allow also the analysis
of B cell clonal evolution and/or ongoing somatic hypermutation.
Nonetheless, we have shown that IgCaller is also able to char-
acterize clonal tumor rearrangements in the context of con-
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Fig. 4 Sequencing depth and tumor purity requirements for IgCaller. a Sensitivity of IgCaller to detect a complete and productive IGH or IGK/L
rearrangement at different ranges of coverage for CLL and MCL cases. b Downsampling experiment with 29 tumor samples. The sensitivity of IgCaller is
shown for each specific mean coverage analyzed. c Identity for IGH (top) and IGK/L (bottom) gene rearrangements for each case at different
downsampling conditions. d Sensitivity of IgCaller at distinct tumor cell contents after mixing tumor/normal (T/N) pairs at different ratios. The mean depth
was set to 30×. e Similar to d but with a mean depth of 60×. Note that only purities of 50%, 35%, 20%, and 5% were analyzed. f Ig gene identity according
to tumor cell content in different T/N mixing conditions. g Sensitivity of IgCaller when tumor samples are mixed with a polyclonal-like population. h
Oligoclonal situation created in silico by mixing at different ratios two tumor samples carrying two IGH rearrangements each; one productive (Prod.) and
one unproductive (Unprod.). The score of each rearrangement according to IgCaller is shown. A score of 0 is used for illustrative purposes for
rearrangements not identified in a specific mixing condition. The score is calculated based on the number of reads supporting each rearrangement
(“Methods”). Source data are provided as a Source data file.
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IgCaller was able to identify multiple productive and unproduc-
tive Ig rearrangements within the same tumor sample allowing
the characterization of oligoclonal tumor populations.
Altogether, the complete characterization of the rearranged Ig
gene based on short-read WGS data, when available, could
facilitate the analysis of IGLC rearrangements, CSR, and onco-
genic Ig translocations, and replace the standard SSeq/NGS/FISH
of the Ig loci both in research and clinical settings.
Methods
Input files. IgCaller extracts the reads of interest from already aligned WGS data
(BAM files) avoiding to re-align the entire data set with custom or specific tools.
The functionality of this program was verified aligning the raw reads using the
BWA-MEM algorithm (v0.7.15 and v0.7.17)23 with default parameters, and con-
verting SAM files to BAM files using either samtools (version 1.6 and 1.9)24 or
biobambam2 (v2.0.65, https://gitlab.com/german.tischler/biobambam2).These
programs are widely accepted and virtually the default algorithms used in most
cancer genomics projects25. However, IgCaller should work well (or be easily
adapted to work well) with any BAM file obtained using any of the available
algorithms designed to align and process paired-end WGS data.
In addition to the WGS BAM file of the B cell neoplasm of interest (hereafter
tumor sample or tumor BAM file), the reference genome used to align the raw
reads and/or the BAM file of the germ line of the patient (hereafter BAM file of the
normal sample) are required to reconstruct the mutated rearranged sequence and
to assess its identity to the germ line. If the normal BAM file is available, it is used
to account for individual polymorphisms. If a given position is not fully covered in
the normal BAM file, the nucleotide present in the reference genome is considered.
If the reference genome is not available, these uncovered positions are not
considered in the identity calculation and reported as N in the output sequence. If
the normal BAM file is not available, the germ line sequence is directly extracted
from the reference genome. Note that the reference genome does not include
information regarding the presence of polymorphisms. Then, if the normal BAM
file is missing, polymorphisms will be considered to be mutations rather than germ
line polymorphisms, which will negatively influence the identity of the rearranged
IGHV sequence detected by IgCaller. Therefore, in this scenario, we strongly
recommend analyzing the rearranged sequence obtained by IgCaller using IMGT/
V-QUEST or IgBLAST, which will account for polymorphisms as traditionally
applied for tumor-only SSeq/NGS sequences.
The third required piece of information is the BED files containing the genomic
locations of the V and J genes of IGH/IGK/IGL (wgEncodeGencodeBasicV19 for
hg19, and GencodeV29 for hg38), the CSR regions (Huebschmann et al., in
preparation)26, and the sequences of the annotated D genes (extracted using the
coordinates of the D genes reported in wgEncodeGencodeBasicV19 for hg19 and
GencodeV29 for hg38). Although the user could define their own regions and
sequences, these files are supplied within the IgCaller program both for hg19 and
hg38. A set of optional parameters, which are described in a next section, might be
specified when running IgCaller.
Identification of V-J rearranged pairs and break points. The first step of
IgCaller consists of extracting the reads aligning to the Ig loci from the supplied
tumor and normal BAM files using samtools, and a mini BAM file is temporarily
created to speed up downstream executions. Reads that are not primary align-
ments, supplementary alignments, and PCR or optical duplicates are removed (-F
3318 option in samtools view). Once proper reads aligning to the regions of interest
are extracted, two types of reads are considered to identify potentially rearranged
V–J gene pairs: (i) split reads: soft clipped reads spanning the boundaries of a V
and J gene. Split reads only mapping to a V or J gene but with >20 bp soft clipped
bases (S in CIGAR) with no mapping information (no “SA:” field in the aligned
read) are also labelled as split reads and used as explained below. (ii) Abnormal
insert size reads: read pairs with anomalous insert size (here defined as insert size
>10,000 bp) in which one read maps to a V gene and its pair aligns to a J gene. Note
that one pair of reads might be considered as both split and abnormal insert size
reads due to the fact that one read might be a split read spanning the V–J
boundaries while its pair might map to the J or V gene. It is important to notice
here that reads do not map to the D gene of the IGH locus due to is small length.
Once split reads and abnormal insert size reads fulfilling the previous considera-
tions are identified, the specific V and J break points are identified based on the
split reads spanning both genes. Then, a score based on the number of split reads (2
points for each read) and abnormal insert size reads (1 point for each pair) is given
to each V–J pair to discriminate likely real V–J rearranged pairs from random
sequencing artifacts. Note that if more than one pair of break points are found for a
given V–J, all of them are kept and considered downstream, but each specific break
will have a different score based on its number of split reads. Besides, if the tumor
purity is known, these scores are adjusted by the tumor cell content of the BAM file
to increase the sensitivity in samples with low tumor purity as well as to make
comparable the rearrangements/scores obtained for different samples.
In the scenario that a given V–J pair is not supported by split reads spanning
both genes (i.e. only identified by abnormal insert size reads), the precise break
points cannot not be identified. This is more likely to occur with extremely short-
read sequencing experiments (i.e. 2 × 90 bp, as some of the samples within the C1-
CLL cohort) than with the new available read lengths (i.e. 2 × 125 bp or 2 × 150 bp,
as applied in C2-CLL, MCL, and MM cohorts). However, if this situation occurred,
all potential combination of breaks coming from split reads mapping only to the V
and to the J genes would be considered.
Once all potential V–J pairs are identified, each of them with their specific break
points, V and J sequences are extracted using samtools mpileup from the start of
the gene to the break point (or from the break point to the end of the gene,
depending on the gene and its orientation in the human genome, see Fig. 1b). If
available, the germ line sequence is obtained from the normal BAM file using the
same set of coordinates/break points, and individual polymorphisms are
considered when assessing the percentage of mutations found in the tumor sample.
In order to increase the sensitivity of our approach, once the J and V sequences
are obtained, split reads mapping only a J or V break of one of the previously
identified J–V pairs with a soft clipped unmapped sequence of >20 bp are
considered to span a V–J pair if ≥5 bp of the soft clipped unmapped sequence can
be mapped to the second break. Thanks to this step, reads spanning J–V
boundaries can be rescued to better discriminate true from artifactual
rearrangements. Besides, it may allow for the identification of the specific break
points of a given V–J pair previously identified by sole abnormal insert size reads.
Extraction of the unmapped junction. Once IgCaller has identified the V–J
breaks, the N nucleotides-D gene-N nucleotides sequence (N-D-N, for IGH) or N
nucleotides (N, for IGK and IGL) between V and J genes are obtained from the
unmapped fraction of the split reads spanning the boundaries of both genes. Thus,
the unmapped sequence of all split reads spanning each specific V-J break are
retrieved, those with the most common length are kept, and only the most
abundant nucleotide in each position is considered to report a unique consensus N-
D-N/N sequence for each V–J specific pair. Note here that if the two most common
N-D-N/N lengths have the same number of supporting reads IgCaller reports both
potential rearrangements. Similarly, if all potential N-D-N/N sequences have dif-
ferent lengths, all of them are reported. To obtain the most likely D gene, a Smith-
Waterman alignment of the N-D-N sequence obtained is performed against all D
gene sequences supplied with a match score of 5 and mismatch and gap costs of 4
and 8, respectively. We noticed some discrepancies in around 10% of the cases
analyzed regarding the D gene obtained from IgCaller’s Smith-Waterman in
comparison to the D gene reported by IMGT/V-QUEST likely due to differences in
the alignment procedure. Therefore, we recommend using IMGT/V-QUEST or
IgBLAST to confirm the D gene reported by IgCaller.
Functionality and identity of the reconstructed sequence. Although the aim of
IgCaller is to retrieve the rearranged sequences of the Ig gene from short-read WGS
rather than to completely assess their functionality (to this aim there are specific
tools such as IMGT/V-QUEST and IgBLAST), IgCaller performs an assessment of
the functionality of the V(D)J (IGH) and VJ (IGK/IGL) sequences obtained. This
assessment is performed by identifying the cysteine (C) 23, tryptophan (W) 41,
cysteine 104, and phenylalanine (F) or tryptophan 118 at the conserved FGXG or
WGXG motif (G, glycine; X, any amino acid). Then the CDR3 region (flanked by
C104 and F/W118) is translated to assess its productivity (i.e. in-frame or out-of-
frame junction). Note that IgCaller removes short insertions within the V gene
before assessing the functionality of a rearranged sequence. In this scenario, a tag is
added in the predicted functionality specifying that indels were found. That said,
note that short insertions are retained in the output sequence of IgCaller to retrieve
the original sequence as would be obtained by SSeq/NGS. Besides, IgCaller also
searches for stop codons within the FR1-FR3 sequence. Although IgCaller was able
to identify the correct functionality of around 95% of the obtained sequences when
compared to IMGT/V-QUEST, we suggest to use specific tools to corroborate these
results.
To assess the identity of the rearranged sequence, the germ line sequence is
obtained from the normal BAM file (if available) or the reference human genome.
The percentage of identity is calculated within the identified FR1 to FR3 regions. If
IgCaller fails in identifying the last C104, the entire sequence of the V gene is used
to calculate an approximate identity. Both the percentage of identity and the
number of nucleotides considered in this calculation are reported.
Locus specific considerations. Due to the inherent differences in the processing
and/or orientation of IGH, IGK, IGL and CSR, each of the analysis performed by
IgCaller have some peculiarities that need to be taken into account for a proper
analysis.
The IGK locus, in addition to the V and J genes, also includes the so-called
intronic recombination signal sequence (RSS, downstream of the J genes) and the
kappa deleting element (Kde, found 24 kb downstream of the constant K region).
Once an unproductive IGK rearrangement is formed, a deletion within the Kde and
RSS may occur to eliminate the constant and enhancer region of the IGK
preventing the expression of the unproductive rearrangement. Similarly, a deletion
involving the Kde and a given V gene may occur to completely eliminate the
unproductive rearrangement28. Both Kde-RSS and Kde-V gene deletions are
investigated by IgCaller to further characterize this locus. Moreover, although the
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IGKJ genes and proximal IGKV genes are oriented on the negative strand, the
IGKV4-1, IGKV5-2, and IGKV genes within the distal cluster are inverted and
therefore oriented on the positive strand. Thus, rearrangements involving the latter
IGKV genes occur by inversions of the IGKV genes rather than deletions.
Regarding the IGL locus it is important to notice that all V and J genes are
oriented in the forward orientation relative to the genome build while IGH is
oriented in the reverse orientation.
For class or isotype switching, IgCaller searches for deletions within the
described CSR of IGHM and IGHA1/2, IGHE or IGHG1/2/3/4 (Huebschmann
et al., in preparation)26. After an inspection of the CSR regions we observed that
split reads may confound a proper identification of the deletions within the CSR
due to their repetitive nature, high similarities within CSR regions, and presence of
a remarkable number of variants and/or sequencing artifacts. Therefore, the use of
split reads in CSR analysis hindered a robust identification of the exact break points
and added noise to the general identification of the potential deletions. As the exact
break points within the CSR are not required to properly assess the isotype switch,
we decided to exclude split reads in this specific analysis. However, in addition to
determine a potential deletion by abnormal insert size reads, the coverage of a 1500
bp window upstream and 1500 bp window downstream of the CSR identified is
compared to assess for a drop of coverage within the deleted region, which will
emphasize the presence of the CSR. For example, if a deletion occurs within the
IGHM and IGHG1, a significant reduction of coverage (or read depth) should be
observed in the region within the IGHM-IGHG1. Therefore, following the previous
example, the coverage of a 1500 bp window upstream of the CSR of the IGHG1 and
a 1,500 bp window downstream of the CSR of IGHG1 is compared using a
Wilcoxon test. Potential class switch deletions with no reduction of coverage are
automatically removed. If the normal WGS is available, the coverage at each
position of the window in the normal BAM file is subtracted to that of the tumor
sample to consider for fluctuations in coverage that are sequence/region specific.
Besides, as applied in the calculation of the score based on the number of reads, the
reduction of the coverage is adjusted by the tumor purity, if available, to increase
the sensitivity of IgCaller in samples with low tumor content. This comparison of
coverage enhanced the specificity of the CSR detection.
Pre-defined filter of low evidence rearrangements. IgCaller performs a pre-
defined filter to highlight high confidence rearrangements while separating them
from low evidence, likely artefactual, sequences. However, both high and low
confidence rearrangements are stored in locus-specific output files. The main two
filters applied to the IGH, IGK and IGL sequences are the requirement of a score
≥3 (after adjusted by the tumor cell content of the sample), and that more than half
of the J and V sequences must contain a nucleotide other than N. Then, if two exact
V(D)J/VJ rearrangements or highly similar V(D)J rearrangements (i.e. sharing two
of the three genes) are found, IgCaller keeps the productive one with the highest
score. For IGK, if IgCaller finds two rearrangements involving the same IGKJ gene
and the same IGKV gene from the proximal and distal cluster, respectively (e.g.
IGKJ2-IGKV2-40 and IGKJ2-IGKV2D-40), it keeps the rearrangement with the
highest score. If both have the same score, the one involving an IGKV gene of the
proximal cluster, which usually has the higher mapping quality, is kept.
When analyzing the CSR, rearrangements considered as high confidence must
have a mean coverage >8× in the upstream window analyzed (the one not affected
by the deletion), a score ≥4 coupled with a reduction of the mean coverage of the
two windows ≥60% or a score ≥7 with a mean reduction of ≥30%, and a p value by
Wilcoxon test <1e-10. This double combination of score and reduction of coverage
allows CSR strongly supported either by a remarkable drop of read depth or by a
high number of reads spanning the deletion. Note that if more than one class
switch deletion passes the previous filters, only the one with the highest reduction
of coverage will be reported in the high confidence output file. In our experience,
nearly all IGH V(D)J sequences identified by SSeq/NGS, productive kappa or
lambda rearrangements matching the light chain expression, and isotypes
identified by FC were called as high confidence rearrangements within the high
confidence passing rearrangements. However, we recommend to check low-
confidence rearrangements specially when analyzing low coverage and/or very
short-read (i.e. 90 bp) WGS data, or if there is an interest in identifying minor
subclonal populations carrying distinct Ig rearrangements.
Genome-wide analysis of oncogenic Ig rearrangements. In addition to char-
acterize the rearranged V(D)J sequences and the presence of CSR, IgCaller sear-
ches for Ig rearrangements genome-wide. In this regard, any potential deletion,
inversion or gain with one break within any of the Ig loci (IGH, IGK or IGL) is
annotated if more than X (4 by default) abnormal insert sizes and/or split reads
mapping to a distant location of the chromosome (>10,000 bp) are found within a
distant <1000 bp from one another. Translocations are identified based on read
pairs in which one read maps to an Ig locus while its pair maps to a different
chromosome. Split reads mapping to both chromosomes are also considered. The
break points reported correspond to the most 5′ position in the positive strand,
and the most 3′ position in the negative strand. Considering that to speed up the
execution of IgCaller it only works with reads aligned to the Ig loci, the non-Ig
break point might not be called precisely at a single-base resolution if split reads
supporting the rearrangement are not found. In this scenario, the approximate
non-Ig break point is extracted from the starting alignment location of the non-Ig
reads (note that the exact break point would correspond to the ending alignment
location for rearrangements/reads mapping to the positive strand, but this
information could only be retrieved looking at the CIGAR information of
that read).
Next, to exclude artifactual rearrangements, the normal BAM file is used, if
available, to annotate the number of reads supporting each potential rearrangement
in the normal sample. In this scenario, a ± 1000 bp window is considered from the
region in which reads supporting the rearrangement were observed in the tumor
sample. Finally, using the default parameters, rearrangements supported by a score
≥10 in the tumor sample and ≤2 reads in the normal BAM file are considered as
high confidence and reported within the passing rearrangements. Besides, both
high and low confidence rearrangements are reported in a specific file for the
genome-wide oncogenic Ig rearrangements. Due to the well-known difficulties on
the detection of rearrangements genome-wide, we recommend to manually review
the alterations found using a visualization tool such as the Integrative Genomics
Viewer (https://software.broadinstitute.org/software/igv) to filter out potential
artifactual rearrangements that could have passed the permissive filters of IgCaller.
Running IgCaller. To run IgCaller it is necessary to have python3 installed with the
following modules: subprocess, sys, os, itertools, operator, collections, statistics,
argparse (v1.1), regex (v2.5.29 and v2.5.30), numpy (1.16.2 and v1.16.3), and scipy
(v1.2.1 and v1.3.0). Although providing the versions of the previous modules
tested, we are not aware about any specific version requirement for running
IgCaller. The only required non-python program is samtools (version 1.6 and 1.9
have been tested).
When running IgCaller the user must define a few mandatory arguments:
inputsFolder (-I): path to the folder containing the supplied IgCaller
reference files.
genomeVersion (-V): version of the reference human genome used when
aligning the WGS data (hg19 or hg38).
chromosomeAnnotation (-C): chromosome annotation [ensembl = without
“chr” (i.e. 1); ucsc = with ‘chr’ (i.e. chr1)].
bamT (-T): path to tumor BAM file.
bamN (-N): path to normal BAM file, if available.
refGenome (-R): path to reference genome FASTA file (not mandatory, but
recommended, when specifying a normal BAM file. Mandatory when bamN not
specified).
There are also some optional arguments:
pathToSamtools (-ptsam): path to the directory where samtools is installed.
There is no need to specify it if samtools is found in PATH (default= empty,
assuming it is in PATH).
outputPath (-o): path to the directory where the output should be stored. Inside
the defined directory IgCaller will automatically create a folder named
tumorSample_IgCaller where output files will be saved (default, current
working directory).
mappingQuality (-mq): mapping quality cut off to filter out reads for Ig V(D)J
reconstruction (default= 0).
baseQuality (-bq): base quality cut off to consider a position in samtools
mpileup when reconstructing both normal and tumor sequences (default= 13).
minDepth (-d): depth cut off to consider a position (default= 1).
minAltDepth (-ad): alternate depth cut off to consider a potential alternate
nucleotide (default= 1)
vafCutoffNormal (-vafN): minimum variant allele frequency (VAF) to consider
a nucleotide when reconstructing the germ line sequence using the supplied
normal BAM file (if available) (default= 0.2).
vafCutoff (-vaf): minimum VAF to consider a nucleotide when reconstructing
the tumor sequence (default= 0.1). Try to increase this value if only
unproductive rearrangements are found due to stop codons. We have observed
that relatively high coverage WGS (i.e. 100×) might carry many variants (likely
sequencing artifacts) at VAFs around 10–20%.
tumorPurity (-p): purity of the tumor sample (i.e. tumor cell content) (default
= 1). It is used to adjust the VAF of the mutations found in the tumor BAM file
before filtering them using the vafCutoff, to adjust the score of each
rearrangement, and to adjust the reduction of read depth in the CSR analysis.
minNumberReadsTumorOncoIg (-mntonco): minimum score supporting an Ig
rearrangement in order to be annotated (default= 4).
minNumberReadsTumorOncoIgPass (-mntoncoPass): minimum score sup-
porting an Ig rearrangement in the tumor sample in order to be considered as
high confidence (default= 10).
maxNumberReadsNormalOncoIg (-mnnonco): maximum number of reads
supporting an Ig rearrangement in the normal sample in order to be considered
as high confidence (default= 2).
mappingQualityOncoIg (-mqOnco): mapping quality cut off to filter out reads
when analyzing oncogenic Ig rearrangements (default= 15).
numThreads (-@): maximum number of threads to be used by samtools
(default= 1).
keepMiniIgBams (-kmb): should IgCaller keep (i.e. no remove) mini Ig BAM
files used in the analysis? (default= no).
As example, the command line to execute IgCaller would be:
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python3 path/to/IgCaller/IgCaller_v1.py -I path/to/IgCaller/IgCaller_reference_
files/ -V hg19 -C ensembl -T path/to/bams/tumor.bam -N path/to/bams/normal.
bam -R path/to/reference/genome_hg19.fa -o path/to/IgCaller/outputs/.
IgCaller was tested on a MacBook Pro (macOS Mojave), Ubuntu (16.04 and
18.04), and MareNostrum 4 (Barcelona Supercomputing Center, SUSE Linux
Enterpirse Server 12 SP2 with python/3.6.1). IgCaller only requires 1 CPU, and it
usually takes <2–5 minutes to characterize the complete Ig gene of one tumor
sample. A longer execution time might reflect the identification of an unusual
larger number of potential rearrangements. A demo data set to run IgCaller is
provided along with the algorithm.
Outputs of IgCaller. The files generated by IgCaller are stored in the output directory
(if specified) or in the current working director inside a folder called tumor_sam-
ple_IgCaller, where tumor_sample is the name of the supplied tumor BAM file (i.e.
tumor_sample.bam). Inside this folder, IgCaller stores several temporary files, which
are removed once the execution finishes, and the following final output files:
tumor_sample_output_filtered.tsv: High confidence rearrangements passing the
pre-defined filters are stored in this file (an example along with a description of
the different fields might be found in Supplementary Data 30).
tumor_sample_output_IGH.tsv: file containing all IGH rearrangements identi-
fied by IgCaller (Supplementary Data 31).
tumor_sample_output_IGK.tsv: file containing all IGK rearrangements identi-
fied by IgCaller (Supplementary Data 31).
tumor_sample_output_IGL.tsv: file containing all IGL rearrangements identi-
fied by IgCaller (Supplementary Data 31).
tumor_sample_output_class_switch.tsv: file containing all CSR rearrangements
identified by IgCaller (Supplementary Data 32).
tumor_sample_output_oncogenic_IG_rearrangements.tsv: file containing all
oncogenic Ig rearrangements (translocations, deletions, inversions, and gains)
identified genome-wide (Supplementary Data 33).
Mutational signature analysis. We used the previously published mutational data
of the 152 C1-CLL cases18,19. Mutational signature analysis was performed as
recently described21. Briefly, we de-novo extracted the mutational signatures found
in the C1-CLL cohort using a non-negative matrix factorization. Signatures extracted
were compared to the single base substitution (SBS) signatures reported in COSMIC
(https://cancer.sanger.ac.uk/cosmic), and the one with the highest cosine similarity
was kept. We identified the presence of signature 1 (or SBS1 in COSMIC), signature
5 (SBS5), signature 8 (SBS8) and signature 9 (SBS9). Next, we measured the con-
tribution of each signature in each case using a fitting approach (MutationalPatterns
R package). To avoid the inter-sample bleeding of signatures21, we iteratively
removed the least contributing signature in each case if the cosine similarity of the
reconstructed mutational profile decreased <0.01. Due to their presence in all normal
and tumor tissues, signatures 1 and 5 were always included if their addition increased
the cosine similarity27. The presence/absence of SBS9 was used as a surrogate of the
mutational status of the C1-CLL patients (M-IGHV or U-IGHV, respectively). An R
script is available within IgCaller to facilitate this analysis.
Orthogonal verification of Ig gene rearrangements. The sequence analysis of the
IGH V(D)J rearrangements by SSeq was performed on either genomic DNA or
complementary DNA using leader or consensus primers for the IGHV FR1 along
with appropriate consensus constant primers18. IGK rearrangements were ampli-
fied using previously described primers12 on 20 ng of genomic DNA. PCR
amplifications were performed using the Taq PCR MasterMix Kit (Qiagen), and
run on a QIAxcel Advanced System (Qiagen). Sanger sequencing was performed
on an ABI Prism BigDye terminator (Applied Biosystems).
The LymphoTrack IGHV Leader Somatic Hypermutation Assay (Invivoscribe
Technologies) was used to characterize IGH V(D)J rearrangements in 68 cases from
the C2-CLL cohort. Libraries were performed using 50 ng of genomic DNA
according to manufacturer recommendations. The bioinformatic analysis was done
using the LymphoTrack MiSeq Data Analysis (version 2.3.1), similar to previous
studies11. Briefly, we considered the top 10 reads after merging those reads that only
differed from 1 or 2 nucleotides, and only reported rearrangements that accounted
for >2.5% of the total number of reads per sample with >90% of the V region
covered. These filters were used to remove rearrangements reflecting potential
contamination of normal B cells and likely artefactual sequences, respectively.
Isotype and light chain expressions were assessed in the laboratory of their
respective hospitals using the antibodies that were routinely tested in each specific
time of assessment.
IMGT/V-QUEST and ARResT/AssignSubsets. The online IMGT/V-QUEST
tool was run using default parameters searching for insertions and deletions in V-
region13,14. The online ARResT/AssignSubsets tool was used to study stereotypy in
CLL cases16.
Downsampling and polyclonal-like WGS data. Downsampling of 29 tumor BAM
files at specific mean sequencing depths (5×, 10×, 15×, 20×, and 25×) was performed
using the samtools. The command used was: samtools view -b -s frac input.bam >
output.bam, where frac was the fraction of reads from the initial BAM file to keep
for each sample and downsampling condition. Similarly, to study normal in tumor
contamination we first downsampled at 30× of mean coverage each tumor and
normal pair. Then, we mixed at different proportion each tumor and normal pair.
Tumor purities studied were 5%, 20%, 35%, 50%, 65%, and 80% at 30× of coverage.
We also analyzed 5%, 20%, 35% and 50% of purity at 60×. The tumor cell content of
the initial 29 tumor samples was summarized as 95% in these analyses considering
that all of them had tumor purities >90%. To create an in silico polyclonal-like
sample we merged 294 tumor BAM files (CLL and MCL) using samtools. Then we
randomly downsampled this merged BAM file to 30×. We next mixed the 29 tumor
samples used in the previous analyses with this polyclonal-like 30× WGS BAM file
at final tumor cell contents of 5%, 20%, 35%, 50%, 65%, and 80%. A oligoclonal
situation was created in silico by mixing at different proportions (0%, 25%, 50%,
75%, and 100%) two CLL samples both carrying a productive and unproductive
IGH gene rearrangement. Note that we used a different seed in samtools for each
experiment (downsampling, normal in tumor contamination, polyclonal-like con-
tamination, and oligoclonal situation) to increase the randomness of the analyses.
IgCaller was run using default parameters in all these experiments.
MiXCR specifications. We run MiXCR (version 3.0.12) using the following
command:
mixcr analyze shotgun -s hsa --starting-material dna --receptor-type bcr --contig-
assembly sample_A_1.fastq.gz sample_A_2.fastq.gz output_folder
MiXCR was run for C1-CLL and MCL samples with available raw sequences to
avoid any bias in the preparation of FASTQ files from previously aligned WGS
data. For each sample, the most abundant Ig clone carrying a productive IGH
rearrangement was used for comparison. The output sequences (called
targetSequences in the output of MiXCR) were used as input of the IMGT/V-
QUEST online tool to compare the functionality and identity of the sequences
obtained. We finally compare the V(D)J rearrangement and CDR3 sequence
identified by MiXCR, SSeq, and IgCaller.
Statistical analyses. Comparison of the percentage of identity to the germ line
between SSeq/NGS and IgCaller was performed using the Passing-Bablok regression
(mcr R package v1.2.1), Pearson correlation coefficient (stats R package v3.5.0), and
Bland-Altman plot (BlandAltmanLeh R package v0.3.1). The clinical relevance of
specific Ig rearrangements was assessed for time to first treatment (TTFT) and
overall survival (OS) calculated from the date of diagnosis to the date of first
treatment/last follow-up and to the date of death/last follow-up, respectively.
Disease-unrelated deaths were considered as competing events in TTFT analyses.
Cumulative incidence curves of TTFT were compared using the Gray test. Multi-
variate analyses of OS were modeled using Cox regression. Clinical analyses were
performed using the survival (v2.42-3) and cmprsk (v2.2-7) R packages. All tests
were two-sided. Based on the analyses performed, we did not apply any adjustment
for multiple comparisons. All analyses were performed in R (version 3.5.0).
General considerations. The study was approved by the Hospital Clińic of Bar-
celona Ethics Committee. Informed consent was obtained for all patients.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequencing data of the C1-CLL cohort, four MCL samples, MM, and DLBCL is available
from the European Genome-phenome Archive (EGA) under accession numbers
EGAS00001001306, EGAS00001000510, EGAS00001001299, and EGAS00001002936,
respectively. Previously unpublished data has been deposited at EGA under accession
numbers EGAS00001004165 (for tumor/normal WGS of 57 MCL cases) and
EGAS00001004298 (Ig reads for C2-CLL and B-NHL cohorts as well as 3 MCL cases). All
other data are included in the supplemental information or available from the authors
upon reasonable requests. Source data are provided with this paper.
Code availability
IgCaller is free-software and is available at https://github.com/ferrannadeu/
IgCaller. Source data are provided with this paper.
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